Cymabay Therapeutics Says Phase 3 RESPONSE Study Of Seladelpar For Primary Biliary Cholangitis Achieved The Primary And All Key Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Cymabay Therapeutics announced that its Phase 3 RESPONSE study of Seladelpar for Primary Biliary Cholangitis has achieved the primary and all key secondary endpoints.
September 07, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cymabay Therapeutics' successful Phase 3 RESPONSE study of Seladelpar could potentially boost its stock price.
The successful completion of a Phase 3 study is a significant milestone for any pharmaceutical company. It often leads to regulatory approval and commercialization of the drug, which can significantly increase the company's revenues and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100